{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzo7g1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzo7g1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/56\\\/7\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/56\\\/7\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/56\\\/7\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/56\\\/7\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EThis article presents the 10-year results of a study comparing taxane type and schedule as a component of adjuvant chemotherapy in localized breast cancer. When administered after doxorubicin-cyclophosphamide, weekly paclitaxel and every-3-weeks docetaxel significantly improved outcomes in the entire study population, while weekly paclitaxel improved outcomes in triple-negative breast cancer.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eadjuvant therapy\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecombination treatment\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eaxillary node positive\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Edisease-free survival\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group drug\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Edoxorubicin\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecyclophosphamide\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epaclitaxel\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EA Phase 3 Study of Doxorubicin-Cyclophosphamide Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EE1199\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EBC\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENCT00004125\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EJoseph A. Sparano, MD, Montefiore Medical Center, Bronx, New York, USA, shared the 10-year results of the E1199 trial: A Phase 3 Study of Doxorubicin-Cyclophosphamide Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer [BC; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00004125\u0026amp;atom=%2Fspmdc%2F14%2F56%2F7.atom\u0022\u003ENCT00004125\u003C\/a\u003E]. In the complete study population, adjuvant weekly paclitaxel and docetaxel Q3W significantly improved outcomes compared with paclitaxel Q3W, when administered sequentially after doxorubicin-cyclophosphamide (AC) therapy, and weekly paclitaxel improved outcomes in patients with triple-negative breast cancer (TNBC).\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EAccording to Dr Sparano, the E1199 trial was designed to compare taxane type and schedule as a component of adjuvant chemotherapy in localized BC [Sparano JA et al. \u003Cem\u003EN Engl J Med.\u003C\/em\u003E 2008]. All participants received 4 cycles of standard AC therapy Q3W, and were randomized to 1 of 4 taxane arms: paclitaxel 175 mg\/m\u003Csup\u003E2\u003C\/sup\u003E Q3W for 4 doses (P3) or 80 mg\/m\u003Csup\u003E2\u003C\/sup\u003E weekly for 12 doses (P1); or docetaxel 100 mg\/m\u003Csup\u003E2\u003C\/sup\u003E Q3W for 4 doses (D3), or 35 mg\/m\u003Csup\u003E2\u003C\/sup\u003E weekly for 12 doses (D1). Patients received hormonal therapy according to standard of care. The primary end point was disease-free survival (DFS).\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EDr Sparano reported that 1639 DFS events and 1283 deaths were recorded in 4950 patients at a median follow-up of 12.1 years. He added that primary comparisons showed no significant difference in outcomes with respect to taxane type (P1\u2009+\u2009P3 vs D1\u2009+\u2009D3; overall survival [OS], log-rank \u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.977; DFS, log-rank \u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.322) or schedule (P1\u2009+\u2009D1 vs P3\u2009+\u2009D3; OS, log-rank \u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.795; DFS, log-rank \u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.876). However, OS (\u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.007) and DFS (\u003Cem\u003EP\u003C\/em\u003E\u2009\u0026lt;\u2009.001) were significant when analyzed using a taxane-by-schedule interaction test, similar to reported 5-year outcomes.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EWith respect to secondary outcomes, there was a significant improvement in DFS (HR, 0.79; 95% CI, 0.68 to 0.90) and a trend toward increased OS (HR, 0.86; 95% CI, 0.73 to 1.00) with D3 compared with P3. Similar results were reported for DFS (HR, 0.84; 95% CI, 0.73 to 0.96) and OS (HR, 0.87; 95% CI, 0.75 to 1.02) for P1 compared with P3.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EWith respect to BC subtype, P1 was the most effective taxane regimen in patients with TNBC (n\u2009=\u20091025). This regimen was associated with increased OS (75% vs 66%; HR, 0.69, 95% CI, 0.50 to 0.94; \u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.094) and DFS (69% vs 59%; HR, 0.69; 95% CI, 0.52 to 0.91; \u003Cem\u003EP\u003C\/em\u003E\u2009=\u2009.032; \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E) compared with standard therapy (P3). Dr Sparano added that similar benefits were not seen with D3.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/56\/7\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Improvement in DFS With Weekly Paclitaxel in Patients With TNBCDFS, disease-free survival; D1, weekly docetaxel; D3, every-3-weeks docetaxel; P1, weekly paclitaxel; P3, every-3-weeks paclitaxel; TNBC, triple-negative breast cancer.                   a10-y rate, % (95% CI).Reproduced with permission from JA Sparano, MD.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-90506846\u0022 data-figure-caption=\u0022\u0026amp;lt;div xmlns=\u0026amp;quot;http:\/\/www.w3.org\/1999\/xhtml\u0026amp;quot;\u0026amp;gt;Improvement in DFS With Weekly Paclitaxel in Patients With TNBCDFS, disease-free survival; D1, weekly docetaxel; D3, every-3-weeks docetaxel; P1, weekly paclitaxel; P3, every-3-weeks paclitaxel; TNBC, triple-negative breast cancer.                   \u0026amp;lt;sup\u0026amp;gt;a\u0026amp;lt;\/sup\u0026amp;gt;10-y rate, % (95% CI).Reproduced with permission from JA Sparano, MD.\u0026amp;lt;\/div\u0026amp;gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/56\/7\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/56\/7\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/14\/56\/7\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/11637\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-7\u0022 class=\u0022first-child\u0022\u003EImprovement in DFS With Weekly Paclitaxel in Patients With TNBC\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EDFS, disease-free survival; D1, weekly docetaxel; D3, every-3-weeks docetaxel; P1, weekly paclitaxel; P3, every-3-weeks paclitaxel; TNBC, triple-negative breast cancer.\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003E\n                  \u003Csup\u003Ea\u003C\/sup\u003E10-y rate, % (95% CI).\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EReproduced with permission from JA Sparano, MD.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-11\u0022\u003EFor patients whose BC was hormone receptor\u2013positive and human epidermal growth factor receptor-2\u2013negative or of unknown status, Dr Sparano said that, although 5-year data showed a trend for improved outcomes in the taxane arms, this was not consistently seen in the updated analysis. At a median follow-up of 12.1 years in this patient population, there was a nonsignificant trend toward increased OS (81.6% vs 79.6%; HR, 0.87; 95% CI, 0.69 to 1.08) favoring D3 compared with P3. DFS was also improved in this group compared with P3 (75.3% vs 69.4%; HR, 0.76; 95% CI, 0.63 to 0.91). However, similar benefits were not seen in association with P1.\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EAlthough these data demonstrate benefit of AC and weekly paclitaxel therapy in patients with TNBC, Dr Sparano emphasized that outcomes can still be improved in this population. A pending trial [NRG-BR003] will investigate the effect of adding carboplatin to AC and weekly paclitaxel in this setting, he concluded.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/56\/7.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzo7g1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzo7g1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}